How to access Skyrizi from Qatar, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Qatari patient with moderate-to-severe plaque psoriasis, psoriatic arthritis, or moderately-to-severely active Crohn's disease may receive a prescription for Skyrizi (risankizumab) from their treating dermatologist, rheumatologist, or gastroenterologist. Skyrizi is FDA-approved in the United States and manufactured by AbbVie. Access through Qatari hospital pharmacies varies by indication and supply timing, when your indication is not on a local formulary, or the exact dose form you need is not in stock, the named-patient import pathway is the legitimate route.
This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.
Ask about Skyrizi in Qatar
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Skyrizi is a humanised IgG1 monoclonal antibody that selectively inhibits IL-23 via binding the p19 subunit. For plaque psoriasis and psoriatic arthritis it is a subcutaneous injection on a quarterly maintenance schedule after two loading doses; for Crohn's disease it uses an IV induction followed by subcutaneous maintenance. Your treating physician confirms eligibility (severity documentation, endoscopic activity for IBD), TB screening, and the monitoring plan per FDA labeling.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Skyrizi legally importable into Qatar?
Yes, through the Qatar Ministry of Public Health (MoPH) Pharmacy & Drug Control Department named-patient framework. The pathway allows a Qatar-licensed physician to import a medicine not locally registered for the specific indication or dose form when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent registered alternative fits, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.
Skyrizi is registered in many Gulf markets for plaque psoriasis; the Crohn's indication and specific paediatric or induction-dose forms are where named-patient imports most often come in.
How the pathway works, step by step
- Consultation with your treating physician. Severity documentation, endoscopic activity if IBD, and clinical rationale.
- Confirming the import rationale. Indication, dose form, or supply-gap rationale is documented.
- MoPH named-patient application. Your physician or the hospital pharmacy files the application with clinical rationale, patient reference, product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner.
- Cold-chain shipment. Skyrizi ships at 2-8°C with continuous temperature monitoring.
- Arrival and first dose. The dispensing facility releases product for in-clinic or at-home administration after training.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming diagnosis, severity, prior therapies, and Skyrizi as the indicated treatment
- Verification of their Qatar medical licence
- Patient identifier
- TB/infection screening confirmation
- Planned loading/maintenance regimen
Reserve Meds provides a physician documentation kit that bundles the templates MoPH reviewers expect to see for IL-23-class biologics.
Costs and timing
Medicine price: quote on request. You get a written quote for your case before you commit. International cold-chain logistics, MoPH documentation handling, and coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.
We give you a written timeline estimate for your case before you commit. Maintenance doses ship on a rolling basis.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Skyrizi specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for MoPH review.
- Logistics. Cold-chain, temperature-monitored shipment.
- Dedicated case lead. A named point of contact.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating physician.
Frequently asked
Is this legal in Qatar? Yes, when executed through the MoPH named-patient framework with appropriate documentation.
Can Skyrizi be self-injected? For the subcutaneous maintenance dose, yes, patients or caregivers are typically trained for home use. The Crohn's IV induction is clinic-administered.
What if a local IL-23 inhibitor is available? Your physician will consider the locally registered option. Named-patient rationale applies where the specific indication, dose form, or your clinical context points to Skyrizi specifically.
Will private insurance cover this? Cash-pay is the default. Some Qatari insurers reimburse named-patient imports case by case; we supply documentation for your submission but do not process insurance claims directly.
Next step
For Skyrizi coordination in Qatar, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-23.
Frequently asked questions
How can I get Skyrizi in Qatar if it is not approved or available there?
Reserve Meds coordinates US-sourced Skyrizi for patients in Qatar through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for Qatar and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Skyrizi in Qatar through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Skyrizi. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in Qatar, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Skyrizi in Qatar through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Skyrizi to a patient in Qatar?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Skyrizi to your treating physician or hospital pharmacy in Qatar, with appropriate handling for the product.
How long does it take, and what does Skyrizi in Qatar cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Skyrizi in Qatar?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.